There are 2949 resources available
Combination checkpoint inhibitor studies in newly diagnosed and recurrent endometrial cancer
Presenter: Ana Oaknin
Session: GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
Resources:
Webcast
Patient journeys of 2 women with recurrent/advanced EC
Presenter: Robert Coleman
Session: GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
Resources:
Webcast
Conclusion
Presenter: Robert Coleman
Session: GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
Resources:
Webcast
Welcome and Introduction
Presenter: David Spigel
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
Extensive-stage SCLC: Changing the paradigm with immune-oncology combinations
Presenter: David Spigel
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
Unresectable stage III NSCLC: Clinical advances in the implementation of immuno-oncology therapy
Presenter: Johan Vansteenkiste
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
Early stage EGFRm NSCLC: Targeted treatment options following complete surgical resection
Presenter: Tom John
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
Locally advanced or metastatic EGFRm NSCLC: Targeted treatment options to improve outcomes in the first-line setting and beyond progression
Presenter: David Planchard
Session: AstraZeneca - Evolving strategies: Managing treatment of early stage and advanced lung cancers
Resources:
Webcast
Chair’s welcome and introductions
Presenter: Ana Oaknin
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Pioneering with PARP inhibition: rationale for maintenance therapy in newly diagnosed ovarian cancer
Presenter: Thomas Herzog
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast